TSL Thinksmart Limited

RNS Number:1788M
Tissue Science Laboratories PLC
16 November 2006



For immediate release                                           16 November 2006

                        Tissue Science Laboratories plc
                            ("TSL" or the "Company")

                              Directors' Dealings

Tissue Science Laboratories plc announces the subscription for New Ordinary
Shares by five of its directors, Patrick Paul, David Jennings, David Lindop,
Andrew Sealey and Martin Hunt, the intention of which was announced on 23
October 2006 as part of the Placing announced by the Company on 23 October 2006
(the "Placing"). The subscriptions by the five directors are on the same terms
as the other investors in the Placing at the price of 55 pence per New Ordinary
Share, following approval of shareholders at the EGM which took place on 15
November 2006. The New Ordinary Shares were admitted to trading on AIM today.

Patrick Paul, Non-Executive Chairman of the Company, subscribed for 1,014,618
New Ordinary Shares pursuant to the Placing. Prior to the Placing, Mr. Paul was
interested in 5,882,440 Ordinary Shares (representing 19.93 per cent of the
Company's issued share capital). Following completion of the Placing, Mr. Paul
is interested in 6,897,058 Ordinary Shares (representing 19.93 per cent of the
Company's issued share capital, as enlarged by the Placing).

Martin Hunt, Chief Executive Officer of the Company, subscribed for 18,181 New
Ordinary Shares in TSL, representing 0.05 per cent of the issued share capital
of the Company following completion of the Placing (the "Enlarged Issued Share
Capital"). Following the Placing, Mr. Hunt has a total holding of 33,587
Ordinary Shares, representing 0.10 per cent of the Enlarged Issued Share Capital
of the Company.

David Jennings, Finance Director of the Company, subscribed for 13,636 New
Ordinary Shares in TSL, representing 0.04 per cent of the Enlarged Issued Share
Capital of the Company. Following the Placing, Mr. Jennings holds a total of
23,193 Ordinary Shares, representing 0.07 per cent of the Enlarged Issued Share
Capital of the Company.

David Lindop, Non-executive Director of the Company, subscribed for 18,181 New
Ordinary Shares in TSL, representing 0.05 per cent of the Enlarged Issued Share
Capital of the Company. Following the Placing, Mr. Lindop holds a total of
18,181 Ordinary Shares, representing 0.05 per cent of the Enlarged Issued Share
Capital of the Company.

Andrew Sealey, Non-executive Director of the Company, subscribed for 33,979 New
Ordinary Shares in TSL, representing 0.10 per cent of the Enlarged Issued Share
Capital of the Company. Following the Placing, Mr. Sealey holds a total of
230,947 Ordinary Shares, representing 0.67 per cent of the Enlarged Issued Share
Capital of the Company.

Enquiries:

Tissue Science Laboratories Plc                                     01252 369603
Martin Hunt, Chief Executive
David Jennings, Finance Director

Nomura Code Securities Limited
Juliet Thompson                                                     0207 7761204
Clare Terlouw                                                       0207 7761205

Hogarth Partnership Limited                                        0207 357 9477
James Longfield
Sarah Richardson





                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
RDSBFBPTMMJBMFF

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Lug 2023 a Lug 2024